A blood test for multiple cancers underdelivers in trial
A blood test that screens for multiple cancers at once sounded like a turning point. A large randomised trial in the UK tells a more complicated story.
The Galleri test, made by the company Grail, analyses DNA fragments in blood released by tumour cells. The premise is straightforward: an annual test catches cancer early, before symptoms appear. In theory, earlier detection leads to better treatment outcomes and fewer deaths.
The first results from the SYMPLIFY trial, a large randomised study following 143,000 British adults aged 50 to 77, were presented at the American Society of Clinical Oncology conference. The researchers found that the test produced less reduction in cancer mortality than anticipated.
What the study shows
This is the first ever randomised trial of a multi-cancer early detection test (MCED). Participants were randomly assigned to receive the test or standard care. The expected result was a clear drop in cancer deaths. That effect was smaller than hoped.
Commentators note that early detection does not automatically lead to better outcomes. An early-found tumour is not always a dangerous one. And some cancers detected early lead to treatments that cause more harm than the disease itself would have.
Relevance for longevity
Early cancer detection is a central theme in longevity medicine. Many people invest in preventive blood tests hoping to get ahead of disease. This study illustrates how difficult it is to translate demonstrated early detection into demonstrated life extension. Test sensitivity, the proportion of cancers a test actually finds, says nothing about whether detection at that moment genuinely helps.
The study is still ongoing. Longer follow-up may produce different results. But the initial findings urge caution before adopting such tests as routine prevention tools.